Related Experiment Video
Updated: Mar 11, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
799
Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after
R Rosamilio1, V Giudice1, I Ferrara1
1Department of Medicine and Surgery, University of Salerno, Baronissi, Italy.
Translational Medicine @ Unisa
|November 30, 2016
Summary
Bendamustine shows promise for treating refractory/relapsed T-large granular lymphocyte leukemia (T-LGLL). This chemotherapy achieved complete remission in two patients, offering a new option for challenging T-LGLL cases.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- T-large granular lymphocyte leukemia (T-LGLL) is a chronic clonal T-cell disorder.
- Current first-line immunosuppressive therapy is insufficient for refractory/relapsed T-LGLL.
- Limited treatment options exist for patients with persistent or recurrent T-LGLL.
Purpose of the Study:
- To evaluate the efficacy of bendamustine in treating refractory/relapsed T-LGLL.
- To assess the safety and durability of response to bendamustine therapy in T-LGLL.
- To explore bendamustine as a potential therapeutic option for challenging T-LGLL cases.
Main Methods:
- Case series of two refractory/relapsed T-LGLL patients.
- Treatment with bendamustine as a single agent.
- Monitoring for complete remission (CR) and duration of response.
Main Results:
- Complete remission (CR) achieved in both patients within 3-6 months.
- Remission was maintained for at least 20 months in one patient.
- A relapsed patient responded again to bendamustine, achieving prolonged CR.
Conclusions:
- Bendamustine is a feasible therapeutic option for refractory/relapsed T-LGLL.
- Bendamustine demonstrates a favorable safety profile, particularly for elderly patients.
- Further prospective studies are warranted to confirm bendamustine's role in T-LGLL treatment.
